NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT07117760 2025-08-12
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Recruiting
NCT04886986 2025-06-27
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT04614363 2023-08-28
68 Ga-PSMA for High Risk Prostate Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT05627778 2022-11-28
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03545165 2021-08-24
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT03362359 2020-07-27
Ga-68-PSMA-11 in High-risk Prostate Cancer
German Cancer Research Center
Phase 1/2 Completed
NCT02488070 2018-03-20
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Stanford University
Phase 1/2 Completed